Search

Author/Creator Murugesan, Alli

1. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191. Issue 6 (2nd June 2016)

Authors:
Hay, Annette E.; Murugesan, Alli; DiPasquale, Ashley M.; Kouroukis, Tom; Sandhu, Irwindeep; Kukreti, Vishal; Bahlis, Nizar J.; Lategan, Johan; Reece, Donna E.; Lyons, John F.; Sederias, Joana; Xu, Hao; Powers, Jean; Seymour, Lesley K.; Reiman, Tony
Journal:
Leukemia & lymphoma
Issue:
Volume 57:Issue 6(2016:Jun.)
Page Start:
1463
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Evaluation of a Low-Threshold/High-Tolerance Methadone Maintenance Treatment Clinic in Saint John, New Brunswick, Canada: One Year Retention Rate and Illicit Drug Use. (23rd October 2012)

Authors:
Christie, Timothy K. S.; Murugesan, Alli; Manzer, Dana; O'Shaughnessey, Michael V.; Webster, Duncan
Other Names:
Franken Ingmar Academic Editor.
Journal:
Journal of addiction
Issue:
Volume 2013(2013)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search